Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

Literature DB >> 17668369

Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

Abstract

Pfizer Inc is developing maraviroc, a CCR5 receptor antagonist for the treatment of HIV-1 infection and rheumatoid arthritis. In April 2007, the FDA advisory committee voted to approve maraviroc for HIV-1 infection. Phase II and III clinical trials, and post-approval studies are ongoing in both treatment-experienced and -naive HIV patients. Phase II trials have also been initiated in patients with rheumatoid arthritis.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2007 PMID： 17668369

Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472

Keyword Cloud
Cited

24 in total

1. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors: Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal: J Med Chem Date: 2012-01-06 Impact factor: 7.446

2. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.

Authors: Paolo Lusso; Luca Vangelista; Raffaello Cimbro; Massimiliano Secchi; Francesca Sironi; Renato Longhi; Marina Faiella; Ornella Maglio; Vincenzo Pavone
Journal: FASEB J Date: 2011-01-03 Impact factor: 5.191

Review 3. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.

Authors: Guoyan G Xu; Jia Guo; Yuntao Wu
Journal: Curr Top Med Chem Date: 2014 Impact factor: 3.295

Review 4. New players in cytokine control of HIV infection.

Authors: Massimo Alfano; Andrea Crotti; Elisa Vicenzi; Guido Poli
Journal: Curr HIV/AIDS Rep Date: 2008-02 Impact factor: 5.071

Review 5. Targeting CCR5 for anti-HIV research.

Authors: W-G Gu; X-Q Chen
Journal: Eur J Clin Microbiol Infect Dis Date: 2014-06-11 Impact factor: 3.267

6. Trypanosoma cruzi highjacks TrkC to enter cardiomyocytes and cardiac fibroblasts while exploiting TrkA for cardioprotection against oxidative stress.

Authors: Daniel Aridgides; Ryan Salvador; Mercio PereiraPerrin
Journal: Cell Microbiol Date: 2013-03-14 Impact factor: 3.715

Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

1. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

2. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.

Review 3. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.

Review 4. New players in cytokine control of HIV infection.

Review 5. Targeting CCR5 for anti-HIV research.

6. Trypanosoma cruzi highjacks TrkC to enter cardiomyocytes and cardiac fibroblasts while exploiting TrkA for cardioprotection against oxidative stress.

Review 7. Drugs for allosteric sites on receptors.

8. Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.

9. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).

10. Maraviroc in the treatment of HIV infection.